{
    "cancer_info": {
        "cancer_name": "Renal Cell Carcinoma (RCC)"
    },
    "diagnosis_recommendations": {
        "examinations": [
            "History and Physical examination",
            "CBC",
            "Comprehensive metabolic panel (including corrected calcium, creatinine, LDH)",
            "Urinalysis",
            "Abdominal/pelvic CT or MRI with IV contrast (renal protocol)",
            "Chest CT (preferred) or Chest X-ray",
            "Bone scan (if symptomatic or elevated ALP/bone pain)",
            "Brain MRI (if neurological symptoms)",
            "Core needle biopsy (for small masses <3 cm or prior to ablation)",
            "Ureteroscopy or urine cytology (if urothelial carcinoma suspected)",
            "Genetic testing (for early onset ≤46 years, bilateral/multifocal tumors, family history, specific histologies)",
            "Abdominal MRI (for hereditary syndrome screening)",
            "Limited CT (for surgical planning)"
        ]
    },
    "staging_treatment_plans": [
        {
            "staging_criteria": "Stage I (T1a)",
            "risk_group": "",
            "treatment_plans": [
                {
                    "treatment_line": "Primary treatment",
                    "patient_subgroup": "T1a tumors",
                    "plan_name": "Partial nephrectomy",
                    "plan_details": "Preferred for T1a tumors",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "Primary treatment",
                    "patient_subgroup": "T1a tumors with comorbidities",
                    "plan_name": "Active surveillance",
                    "plan_details": "For masses ≤2 cm",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Alternative"
                },
                {
                    "treatment_line": "Primary treatment",
                    "patient_subgroup": "Inoperable T1a tumors",
                    "plan_name": "Ablation",
                    "plan_details": "Cryoablation or RFA for masses ≤3 cm",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Alternative"
                }
            ]
        },
        {
            "staging_criteria": "Stage I (T1b)/II/III",
            "risk_group": "",
            "treatment_plans": [
                {
                    "treatment_line": "Primary treatment",
                    "patient_subgroup": "T1b/II/III tumors",
                    "plan_name": "Radical nephrectomy",
                    "plan_details": "Standard surgical approach",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "Primary treatment",
                    "patient_subgroup": "Feasible T1b/II/III tumors",
                    "plan_name": "Partial nephrectomy",
                    "plan_details": "When technically feasible",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred when feasible"
                },
                {
                    "treatment_line": "Adjuvant therapy",
                    "patient_subgroup": "High-risk ccRCC (stage II-IV NED)",
                    "plan_name": "Pembrolizumab",
                    "plan_details": "Post-nephrectomy adjuvant therapy",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                }
            ]
        },
        {
            "staging_criteria": "Stage IV Resectable",
            "risk_group": "",
            "treatment_plans": [
                {
                    "treatment_line": "Primary treatment",
                    "patient_subgroup": "Select patients with good PS",
                    "plan_name": "Cytoreductive nephrectomy",
                    "plan_details": "± adjuvant pembrolizumab",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                }
            ]
        },
        {
            "staging_criteria": "Stage IV (Metastatic) or Relapsed",
            "risk_group": "Favorable (ccRCC)",
            "treatment_plans": [
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "Favorable risk ccRCC",
                    "plan_name": "Axitinib + Pembrolizumab",
                    "plan_details": "TKI-IO combination therapy",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "Favorable risk ccRCC",
                    "plan_name": "Cabozantinib + Nivolumab",
                    "plan_details": "TKI-IO combination therapy",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "Favorable risk ccRCC",
                    "plan_name": "Lenvatinib + Pembrolizumab",
                    "plan_details": "TKI-IO combination therapy",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                }
            ]
        },
        {
            "staging_criteria": "Stage IV (Metastatic) or Relapsed",
            "risk_group": "Intermediate/Poor (ccRCC)",
            "treatment_plans": [
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "Intermediate/poor risk ccRCC",
                    "plan_name": "Ipilimumab + Nivolumab",
                    "plan_details": "IO-IO combination therapy",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "Intermediate/poor risk ccRCC",
                    "plan_name": "Cabozantinib monotherapy",
                    "plan_details": "TKI monotherapy",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Alternative"
                }
            ]
        },
        {
            "staging_criteria": "Stage IV (Metastatic) or Relapsed",
            "risk_group": "",
            "treatment_plans": [
                {
                    "treatment_line": "Subsequent therapy",
                    "patient_subgroup": "ccRCC after PD-1/VEGF-TKI failure",
                    "plan_name": "Cabozantinib",
                    "plan_details": "Single-agent TKI",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "Subsequent therapy",
                    "patient_subgroup": "ccRCC after prior therapy",
                    "plan_name": "Lenvatinib + Everolimus",
                    "plan_details": "TKI-mTOR inhibitor combination",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "Subsequent therapy",
                    "patient_subgroup": "VHL-associated RCC",
                    "plan_name": "Belzutifan",
                    "plan_details": "HIF-2α inhibitor",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                }
            ]
        },
        {
            "staging_criteria": "Non-Clear Cell RCC (nccRCC)",
            "risk_group": "",
            "treatment_plans": [
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "All nccRCC",
                    "plan_name": "Cabozantinib",
                    "plan_details": "Single-agent TKI",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "nccRCC",
                    "plan_name": "Lenvatinib + Pembrolizumab",
                    "plan_details": "TKI-IO combination",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "Collecting duct/medullary nccRCC",
                    "plan_name": "Platinum-based chemotherapy",
                    "plan_details": "e.g., Carboplatin/Gemcitabine",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                }
            ]
        },
        {
            "staging_criteria": "Oligometastatic Disease",
            "risk_group": "",
            "treatment_plans": [
                {
                    "treatment_line": "Local therapy",
                    "patient_subgroup": "Limited metastases",
                    "plan_name": "Metastasectomy or SBRT/ablation",
                    "plan_details": "Curative-intent local treatment",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                }
            ]
        }
    ],
    "biomarker_clinical_significance": {
        "clinical_significance": [
            "PD-1/PD-L1 status predicts efficacy of immunotherapy (e.g., pembrolizumab)",
            "Sarcomatoid features indicate aggressive disease and improved response to cabozantinib + nivolumab",
            "VHL mutations guide use of belzutifan (HIF-2α inhibitor)",
            "TSC mutations indicate response to everolimus (mTOR inhibitor)",
            "HLRCC (FH-deficient) predicts response to erlotinib + bevacizumab",
            "IMDC/MSKCC risk factors direct first-line therapy selection (e.g., ipilimumab + nivolumab for poor risk)",
            "SDH-deficient RCC associated with PGL/PCC syndromes requiring specific surveillance"
        ]
    },
    "guideline_id": "（2025.V2）NCCN临床实践指南：肾癌.txt"
}